by jtcir-auto | Jan 28, 2020 | Press Releases
– Study P01 is the first of two studies as agreed with the EMA in the Company’s Pediatric Investigation Plan for macimorelin as a growth hormone deficiency diagnostic — Study P01 final study results expected in Q2 2020 -CHARLESTON, S.C., Jan. 28,...
by jtcir-auto | Jan 28, 2020 | Press Releases
– Study P01 is the first of two studies as agreed with the EMA in the Company’s Pediatric Investigation Plan for macimorelin as a growth hormone deficiency diagnostic — Study P01 final study results expected in Q2 2020 -CHARLESTON, S.C., Jan. 28,...
by jtcir-auto | Jan 27, 2020 | Press Releases
CHARLESTON, S.C., Jan. 27, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company engaged in commercializing novel pharmaceutical therapies, today...
by jtcir-auto | Jan 27, 2020 | Press Releases
CHARLESTON, S.C., Jan. 27, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company engaged in commercializing novel pharmaceutical therapies, today...
by jtcir-auto | Jan 8, 2020 | Press Releases
CHARLESTON, S.C., Jan. 08, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today announced that it has received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because the closing bid...
by jtcir-auto | Jan 8, 2020 | Press Releases
CHARLESTON, S.C., Jan. 08, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today announced that it has received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because the closing bid...